Sold as Trisoralen. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Trioxsalen (sold as Trisoralen), first approved Jul 24, 1964, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural MesotheliomaEpitheliod Malignant Pleural Mesothelioma · Abramson Cancer Center at Penn Medicine | Phase 2 | Active, not recruiting | Jun 3, 2014 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 24, 1964 | TrisoralenNDA 12697 · New molecular entity | Valeant Pharm Intl | 8 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
